To minimize these risks, strategies including biomarker‐guided patient selection, E‐cadherin, vimentin, EMT‐associated miRNAs, optimized fractionation, spatially precise RT using IMRT, and tumor‐specific delivery systems for nanoparticles and exosomes can be used [176]. Here, CDH1 is linked to neoplasm.